UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 471,902 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 96.9% in the 4th quarter, HoldingsChannel reports. The firm owned 958,671 shares of the biopharmaceutical company’s stock after buying an additional 471,902 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Amicus Therapeutics were worth $9,031,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of FOLD. Virtus Fund Advisers LLC bought a new stake in shares of Amicus Therapeutics in the 4th quarter valued at about $29,000. Covestor Ltd raised its holdings in shares of Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 2,312 shares in the last quarter. R Squared Ltd bought a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $79,000. KBC Group NV raised its stake in shares of Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 3,120 shares in the last quarter. Finally, Sciencast Management LP bought a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $100,000.

Wall Street Analyst Weigh In

Several research firms recently commented on FOLD. Wall Street Zen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. The Goldman Sachs Group reduced their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research note on Friday, May 2nd. UBS Group boosted their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, Wells Fargo & Company reduced their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $16.22.

Amicus Therapeutics Stock Down 1.6%

NASDAQ:FOLD opened at $6.11 on Friday. The company has a market cap of $1.88 billion, a PE ratio of -33.94, a P/E/G ratio of 1.51 and a beta of 0.64. Amicus Therapeutics, Inc. has a twelve month low of $5.81 and a twelve month high of $12.65. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company’s 50 day moving average is $6.83 and its two-hundred day moving average is $8.57.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.